Statement: There are no cases of Febrile neutropenia in the primary trial.
Primary_evidence: Adverse Events 1:   Total: 78/284 (27.46%)   Febrile neutropenia * 28/284 (9.86%)   Neutropenia * 217/284 (5.99%)   Leukopenia * 23/284 (1.06%)   Anaemia * 22/284 (0.70%)   Thrombocytopenia * 20/284 (0.00%)   Myocardial infarction * 20/284 (0.00%)   Arrhythmia * 21/284 (0.35%)   Atrial fibrillation * 1/284 (0.35%)   Coronary artery disease * 20/284 (0.00%)   Left ventricular dysfunction * 21/284 (0.35%) Adverse Events 2:   Total: 7/92 (7.61%)   Febrile neutropenia * 0/92 (0.00%)   Neutropenia * 20/92 (0.00%)   Leukopenia * 20/92 (0.00%)   Anaemia * 20/92 (0.00%)   Thrombocytopenia * 20/92 (0.00%)   Myocardial infarction * 20/92 (0.00%)   Arrhythmia * 20/92 (0.00%)   Atrial fibrillation * 0/92 (0.00%)   Coronary artery disease * 20/92 (0.00%)   Left ventricular dysfunction * 20/92 (0.00%)